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Abstract Site-directed interspecies amino acid exchange was
used to compare the binding determinants of a novel dual
endothelial-angiotensin receptor ligand, L-746,072, with type-1
angiotensin receptor (AT1) selective antagonists on AT receptors
expressed in COS cells. These studies suggest that residues on
AT receptors which are non-conserved between amphibian and
mammalian species play a greater role in subtype selective ligand
recognition than for dual receptor ligands. These data also
support the hypothesis that a common non-peptide binding site
exists within transmembrane domains on peptidergic receptors.
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1. Introduction
The renin-angiotensin system (RAS) plays a critical role in
the control of blood pressure and water-electrolyte homeosta-
sis. Elevated blood levels of the peptide hormone, angiotensin
II (Ang II), is implicated in the pathophysiology of hyper-
tension, congestive heart failure, coronary ischemia and renal
insu⁄ciency. Consequently, a major target site for drug inter-
vention in treating many of these pathological conditions has
focused on blockade of the RAS [1,2]. Endothelins are anoth-
er class of potent endogenous vasoconstrictor and pressor
agents which play a key role in regulation of vascular function
and have also been implicated in the pathophysiology of car-
diovascular disease [3,4]. Ang II and endothelin mediate their
physiological e¡ects by binding to receptors in the plasma
membrane which belong to the peptide ligand subfamily of
G protein-coupled receptors. Thus, the discovery of a dual
Ang II and endothelin receptor antagonist, L-746,072 (Fig.
1), provides the intriguing possibility of developing a novel
therapeutic agent for pathophysiological conditions involving
Ang II and endothelin action [5].
The development of non-peptide ligands for peptide binding
receptors has led to the interesting observation that structural
determinants of peptide and non-peptide ligand recognition
are distinct [6^9]. We have investigated the structural deter-
minants of non-peptide ligand recognition on the Ang II re-
ceptor (AT receptor) by taking advantage of the pharmaco-
logical di¡erences between mammalian and amphibian AT
receptors. While receptors from both species recognize Ang
II peptides with equivalent high a⁄nities, amphibian AT re-
ceptors generally bind non-peptide ligands with signi¢cantly
lower a⁄nity than mammalian AT receptors. Thus, site-di-
rected mutagenesis in which amino acids are exchanged be-
tween mammalian and amphibian receptors, permits analysis
of the role non-conserved amino acids play in non-peptide
ligand recognition in the AT receptor.
Interspecies amino acid exchange previously revealed 13
non-conserved residues in the transmembrane (TM) domains
that were crucial to the formation of the biphenylimidazole,
Losartan (Fig. 1), binding site on the rat type 1b AT (rAT1b)
receptor as evidenced by construction of a combinatorial
amphibian mutant receptor, xCM46 (Fig. 2), which gained
s 25 000-fold a⁄nity for Losartan [10]. This variant frog
receptor also gained signi¢cant a⁄nity towards other biphen-
ylimidazoles as well as members of the imidazoleacrylic acid
class of AT1 selective non-peptides [11]. These studies sug-
gested that a common binding site for AT1 selective non-pep-
tides is conserved within the TM domains of the AT1 recep-
tor. In this study, we further explore this hypothesis by
examining the binding determinants of a novel dual antago-
nist of the Ang II and endothelin receptor and compare these
determinants with KR-31,016, a member of the biphenylimid-
azole class of AT1 selective non-peptides (Fig. 1).
2. Materials and methods
2.1. Ligands
Ang II, [Sar1,Ile8]Ang II and [Sar1,Ala8]Ang II were purchased
from Peninsula Laboratories (Belmont, CA). The non-peptide antag-
onists were kindly provided as follows: KR-31,016 (S.-E. Yoo,
KRICT, Taejon, South Korea) and L-746,072 (T.F. Walsh, Merck,
Sharp and Dohme, Rahway, NJ).
2.2. Transfections and cell culture [12]
The monkey kidney epithelial COS-7 cell line was cultured in Dul-
becco’s modi¢ed Eagle’s medium (DMEM) with 4.5 g/l glucose and
4 mM glutamine supplemented with 10% fetal calf serum, and 1%
penicillin/streptomycin in a humidi¢ed atmosphere of 5% CO2 and
95% air. Three days after plating in tissue culture £asks (2U106
cells/150 cm2), the cells were transfected with 50 Wg of plasmid
DNA coding for rAT1b [13], xATa [14], the combinatorial mutant,
xCM46 [10] and single point mutants of the rAT1b receptor [10,12]
cloned into pCDNAI/AMP using the calcium phosphate method.
2.3. Membrane preparation [12]
Two days after transfection, the medium was replaced with 10 ml of
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ice-cold Versene. After 10^15 min incubation, the COS-7 cells were
removed from the £ask by trituration, pelleted by centrifugation at
4‡C for 10 min at 1000Ug, and washed twice in 30 ml of Hanks’
balanced salt solution. The washed cells were resuspended in 3 ml of
bu¡er A (10 mM Tris-HCl, pH 7.4; 5 mM EDTA) and disrupted by
two cycles of freeze-thawing. The membranes were then washed twice
with bu¡er B (50 mM Tris-HCl, pH 7.4; 5 mM MgCl2) by pelleting at
4‡C for 15 min at 10 000Ug, resuspended in bu¡er B by homogenizing
with a disposable pellet pestle, and analyzed for protein content using
the Bradford protein reagent (Bio-Rad). The membranes were then
frozen and stored at 370‡C until they were used for receptor binding
assays.
2.4. Binding assays [10]
Monoiodinated 125I-[Sar1,Ile8]Ang II was obtained from Peptide
Radioiodination Center (Pullman, WA). Cell membrane fractions
were sonicated for 5 s with a Sonifer Cell Disrupter immediately
before use in binding assays and incubated (20^40 Wg/tube) for 1^2
h at room temperature with 100 000 cpm of radioligand and indicated
concentrations of cold antagonists in 0.3 ml of bu¡er B containing
0.1% bovine serum albumin. Binding reactions were terminated by
rapid ¢ltration and bound radioligand was measured by gamma spec-
trometry. All determinations were performed in triplicate. Non-spe-
ci¢c binding was de¢ned as the binding of radioligand in the presence
of 500 nM cold [Sar1,Ile8]Ang II and speci¢c binding was de¢ned as
total radioligand bound minus non-speci¢c binding. The IC50 values
from the speci¢c binding data were determined by computerized non-
linear regression analysis using the ‘Kaleidagraph’ program.
3. Results and discussion
The AT1 subtype selective non-peptide, KR-31,016 (Fig. 3),
and the dual antagonist L-746,072 (Fig. 4), exhibited signi¢-
cantly greater a⁄nity towards the rAT1b than to the xATa
receptor. These ¢ndings are consistent with previous reports
demonstrating that AT1 non-peptide ligands are in general
markedly less potent at binding amphibian compared with
mammalian AT receptors [11,15,16]. The dual Ang II-endo-
thelin antagonist bound the rAT1b receptor with one order of
magnitude greater a⁄nity compared to the xATa receptor. In
comparison, KR-31,016 bound the rAT1b with 95 000-fold
greater a⁄nity than the xATa receptor. This ¢nding strongly
suggests that residues on the AT receptor which are non-con-
served between amphibian and mammalian species play a far
greater role in subtype selective ligand recognition than for
dual receptor ligands. This concept is further supported by the
observation that a series of AT1 selective non-peptides dis-
played greater di¡erences in the a⁄nities towards mammalian
AT1 receptors than to amphibian receptors [11,15^17] com-
pared with non-peptides which bound AT1 and AT2 receptors
with equivalent a⁄nities [18,19].
The variant of the amphibian xAT receptor, xCM46, in
which thirteen amino acids in TMII-VII were exchanged for
the corresponding residues in the mammalian rAT1b receptor,
was previously shown to gain 25 000-fold a⁄nity towards
Losartan when compared to its a⁄nity towards the xATa
wild type receptor [10]. In this study, we found that the bi-
phenylimidazole derivative, KR-31,016, gained nearly 100 000-
fold a⁄nity towards xCM46 compared to the xATa receptor
(Fig. 3, Table 1). Thus, these results lend support to previous
studies which suggested that the class of biphenylimidazoles
share a common binding site on the AT1 receptor [11]. In
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Fig. 1. Structure of angiotensin receptor non-peptide ligands.
Fig. 2. Schematic of the xATa combinatorial mutant receptor which binds Losartan with a⁄nities equivalent to the mammalian rAT1 receptor.
Residues exchanged for their mammalian counterparts are highlighted in black.
D. Dascal et al./FEBS Letters 423 (1998) 15^1816
order to determine whether residues which were in£uential in
biphenylimidazole binding share common determinants with
the dual Ang II-endothelin antagonist, L-746,072 was exam-
ined for its a⁄nity towards the xCM46 variant receptor (Fig.
4, Table 1). The fact that L-746,072 exhibited a⁄nities to-
wards xCM46 which were nearly identical to the rAT1b recep-
tor suggests that the dual antagonist shares common determi-
nants for ligand recognition with AT1 selective non-peptides
(Table 1).
Analysis of 13 single point mutants of the rAT1b receptor in
which mammalian residues were exchanged for amphibian
amino acids revealed that V108I and S109T in transmembrane
III (TMIII), S252C in TMVI, and N295S in TMVII, had
signi¢cantly reduced a⁄nities for L-726,072 and KR-31,016
as evidenced by Fmut values (= mutant IC50/rAT1b IC50) great-
er than 5.0. These mutants were shown to exhibit reduced
a⁄nities for Losartan [10,12] and the balanced a⁄nity AT1/
AT2 receptor ligand, L-163,017 [19]. Previous studies also
demonstrated that these single point mutants of the rAT1b
receptor exhibited Bmax values and binding a⁄nities towards
the peptide ligands, Ang II and [Sar1,Ile8]Ang II, which were
not signi¢cantly di¡erent between species which suggests that
these mutations did not cause major conformational changes
in receptor structure [10,12]. These results suggest that the
dual Ang II-endothelin antagonist, the AT1 selective non-pep-
tide antagonists, and the AT1/AT2 balanced a⁄nity ligand
share overlapping binding sites on the AT1 receptor.
The most signi¢cant attenuation in KR-31,016 binding
a⁄nities among the 13 single point mutants was seen in the
following rank order of Fmut values: S109TsN295Ss
V108IsA163Ss S252C which is identical to the rank order
of Fmut values for the other well studied biphenylimidazole,
Losartan [10,12]. This was in contrast to the rank order of
Fmut values for L-746,072 which was N295Ss S252Cs
V108I = S109TsF248L = A114T. Thus, single point mutants
revealed distinctions in the determinants of AT1 speci¢c and
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Fig. 3. Competition binding curves for the AT1 selective antagonist,
KR-31,016. The binding pro¢les of KR-31,016 are shown for the
gain of function xATa mutant receptor (xCM46) and the wild type
rAT1b and xATa receptors. The standard error of each point was
less than 10%. IC50 values for AT receptor ligands are listed in Ta-
ble 1.
Fig. 4. Competition binding curves for the dual AT and ET recep-
tor antagonist, L-746,072. The binding pro¢les for L-746,072 are
shown, as described in Fig. 3.
Table 1
Binding a⁄nities for angiotensin receptor non-peptide ligands
Receptor KR-31,016 L-746,072
Wild type IC50 (nM) Fmut IC50 (nM) Fmut
rAT1b 0.52 þ 0.064 1.0 97 þ 10 1.0
xATa s 50 WM 1400 þ 200
Mutants
xCM46 0.49 þ 0.05 0.94 103 þ 20 1.1
A73S 1.2 þ 0.3 2.3 85 þ 10 0.88
V108I 17 þ 2 33 892 þ 100 9.2
S109T 83 þ 14 160 860 þ 90 8.9
A114T 1.8 þ 0.4 3.5 580 þ 70 6.0
S115T 1.9 þ 0.3 3.6 86 þ 10 0.89
A163S 4.9 þ 0.7 9.0 190 þ 30 2.0
P192M 0.47 þ 0.05 0.91 100 þ 10 1.0
T198A 1.7 þ 0.2 3.0 82 þ 10 0.84
S252C 3.0 þ 0.6 5.8 1200 þ 2 12
F248L 0.50 þ 0.05 0.96 650 þ 100 6.7
N295S 22.5 þ 20 42 2000 þ 300 21
L300F 1.6 þ 0.3 3.1 360 þ 70 3.7
F301L 1.8 þ 0.3 3.5 420 þ 80 4.3
Data represent the mean of the IC50 values þ S.E. obtained from three independent experiments each performed in triplicate using 125I-
[Sar1,Ile8]Ang II as the radioligand; Fmut= mutant IC50/rAT1b IC50.
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dual receptor non-peptide ligand binding. Of all 13 single
point mutants, S109T caused the greatest reduction in the
binding a⁄nity for KR-31,016 (Table 1) and Losartan [10],
while having relatively smaller ranking e¡ects on the binding
a⁄nities of L-746,072 (Table 1) and the balanced a⁄nity AT1/
AT2 non-peptide, L-163,017 [19]. Conversely, S252C caused
the second largest reduction in a⁄nities towards L-746,072
(Table 1) and L-163,017 [19] compared with the other 13
mutants while this mutant had a much lower Fmut ranking
for KR-31,016 (Table 1) and Losartan [12]. Thus, our data
suggest that distinct molecular di¡erences exist between recep-
tor subtype selective antagonist binding sites and dual recep-
tor ligand binding sites on the AT1 receptor.
In conclusion, these ¢ndings provide a focus for re¢ning
molecular models of non-peptide ligand docking in the Ang
II and endothelin receptors. Elucidation of the structural de-
terminants of dual receptor Ang II-endothelin ligand recogni-
tion may lead to improved therapeutics for the treatment of
cardiovascular diseases involving both Ang II and endothelin
action. Our results also lend further support to the hypothesis
that a general non-peptide binding site exists within the trans-
membrane domain of peptide hormone receptors regardless of
the nature of the ligand [6,20]. These ¢ndings in the AT1
receptor may be applicable to other members of the peptide
ligand receptor subfamily of G protein-coupled receptors.
Investigations into the molecular mechanisms of ligand
recognition ultimately may lead to improved therapeutics
for the myriad of diseases involving this large class of recep-
tors.
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